Definitely. The class as a whole appears broadly useful. Rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, lupus and psoriatic arthritis are all being tested by GLPG/GILD or INCY/LLY.
I did catch that. The relevant bit for me was:
I guess you could say INCY/LLY were a bit unlucky, in a sense. Reading that passage, it sounds to me like an issue that may have arisen with long term treatment and became visible to the FDA with the additional data package. If so, this may be a very long delay.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.